← Back to Analyst Consensus 
ARQT Buy
Arcutis Biotherapeutics, Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 2 firms
Next Earnings
Nov 4, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Oct 15, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Aug 6, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 6, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 6, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| May 7, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 2, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Feb 27, 2026 | Guggenheim | maintain | Buy → Buy | $35 | 52% |
| Feb 26, 2026 | TD Cowen | maintain | Buy → Buy | $35 | 54% |
| Feb 26, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $34 | 44% |
| Feb 26, 2026 | Needham | maintain | Buy → Buy | $36 | 50% |
| Jan 26, 2026 | Needham | maintain | Buy → Buy | $31 | 50% |
| Nov 28, 2025 | Mizuho | maintain | Outperform → Outperform | $37 | 52% |
| Oct 30, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $29 | 54% |
| Oct 28, 2025 | Needham | maintain | Buy → Buy | $30 | 50% |
| Aug 7, 2025 | Needham | maintain | Buy → Buy | $22 | 50% |
| Jul 25, 2025 | Goldman Sachs | initiate | — → Neutral | $18 | 54% |
| May 23, 2025 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Apr 9, 2025 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Apr 3, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Apr 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Apr 3, 2025 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Mar 11, 2025 | Jefferies | maintain | Buy → Buy | $19 | 52% |
| Feb 27, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $15 | 54% |
| Feb 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Feb 26, 2025 | Mizuho | maintain | Outperform → Outperform | $21 | 52% |
| Feb 26, 2025 | Needham | reiterate | Buy → Buy | $20 | 50% |
| Feb 24, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Feb 10, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Jan 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Jan 7, 2025 | Mizuho | maintain | Outperform → Outperform | $20 | 52% |
| Dec 30, 2024 | HC Wainwright & Co. | initiate | — → Buy | $19 | 44% |
| Dec 17, 2024 | Needham | maintain | Buy → Buy | $20 | 50% |
| Nov 7, 2024 | Needham | reiterate | Buy → Buy | $18 | 50% |
| Aug 28, 2024 | Jefferies | initiate | — → Buy | $15 | 52% |
| Aug 15, 2024 | Needham | reiterate | Buy → Buy | $18 | 50% |
| Jul 30, 2024 | Needham | reiterate | Buy → Buy | $18 | 50% |
| Jul 10, 2024 | Needham | reiterate | Buy → Buy | $18 | 50% |
| May 15, 2024 | Needham | maintain | Buy → Buy | $18 | 50% |
| May 15, 2024 | Mizuho | maintain | Buy → Buy | $18 | 52% |
| Apr 12, 2024 | Needham | reiterate | Buy → Buy | $16 | 50% |
| Feb 28, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $11 | 54% |
| Feb 28, 2024 | Mizuho | reiterate | Buy → Buy | $17 | 52% |
| Feb 28, 2024 | Needham | maintain | Buy → Buy | $16 | 50% |
| Feb 23, 2024 | Mizuho | reiterate | Buy → Buy | $16 | 52% |
| Jan 3, 2024 | Mizuho | upgrade | Neutral → Buy | $8 | 52% |
| Jan 2, 2024 | Mizuho | upgrade | Neutral → Buy | $8 | 52% |
| Nov 13, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $10 | 54% |
| Nov 8, 2023 | JonesTrading | downgrade | Buy → Hold | $0 | 75% |
| Nov 6, 2023 | Needham | maintain | Buy → Buy | $8 | 50% |
Price Target Trend
Jun 27, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days